Targeting of cytokine secreting lymphocyte (TCSL) group

Dr Jandus main scientific interest is in the study of T cell- and Innate Lymphoid Cell (ILC)- mediated immune responses to human tumors. She has adopted and developed cutting-edge technologies for high-throughput analyses of T cells, at the single cell level, allowing to focus on the quantitative and qualitative evaluation of natural and therapy-induced tumor-specific CD4 T cell responses. She aims to identify the most potent T cells and best-of-class T cell receptors (TCRs), enabling their rapid and cost-effective isolation and validation in clinical trials. In parallel, she is investigating the role of Innate lymphoid cell (ILC) subsets, a recently described family of innate immune effector cells, in the context of anti-tumor immunity. She has been pioneering in reporting the pro-tumoral role of the ILC2 subset in human tumors and she is currently developing strategies to target these cells therapeutically in patients.

Specific expertise

  • Multiparamtric, flow-cytometry based human Innate and adaptive lymphocyte profiling
  • Single-cell nanobiosensors
  • Immunotherapy

Selected publications

Trabanelli S, Ercolano G, Wyss T, Gomez-Cadena A, Falquet M, Cropp D, Imbratta C, Leblond MM, Salvestrini V, Curti A, Adotevi O, Jandus C* & Verdeil G*. c-Maf expression enforces trained-like functional features in mouse and human ILC2s. EMBO, 2022 Jun 14;41(12):e109300. *Shared last authorship

Ercolano G, Gomez-Cadena A, Dumauthioz N, Vanoni G, Kreutzfeldt M, Wyss T, Michalik L, Loyon R, Ianaro A, Ho P-C, Borg C, Kopf M, Merkler D, Krebs P, Romero P, Trabanelli S and Jandus C. PPARg drives IL-33 dependent ILC2 pro-tumoral functionsNat Communications, 2021 May; 12(1):2538

Cachot A, Bilous M, Liu Y-C, Li X, Saillard M, Cenerenti M, Rockinger GA, Wyss T, Guillaume P, Schmidt J, Genolet R, Ercolano G, Protti MP, Reith W, Ioannidou K, de Leval L, Trapani JA, Coukos G, Harari A, Speiser DE,  Mathis A, Gfeller D, Altug H, Romero P and Jandus C. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Science Adv, 2021 Feb, 7(9):eabe3348

Rockinger AG., Guillaume P., Cachot A., Saillard M., Speiser DE., Coukos G., Harari A., Romero P., Schmidt J. and Jandus C. Optimized combinatorial pMHC class II multimer labelling for precision immune monitoring of tumor-specific CD4 T cells in patients. JITC, 2020 May, 8(1):e000435

Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclément C, Bohner P, Bruni E, Girorta M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derré L and Jandus C. Tumor-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun, 2017 Sep, 8(1):593

7 Apr 2022